Koers PHARMING GROUP Euronext Amsterdam
Aandelen
NL0000377018
Farmaceutische producten
slotkoers
Andere beurzen
|
||
- EUR | - |
Omzet 2024 * | 262 mln. 280 mln. | Omzet 2025 * | 300 mln. 321 mln. | Marktkapitalisatie | 606 mln. 648 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 1 mln. 1,07 mln. | Nettowinst (verlies) 2025 * | 14 mln. 14,97 mln. | EV/omzet 2024 * | 1,97 x |
Nettoliquiditeiten 2024 * | 90,86 mln. 97,15 mln. | Nettoliquiditeiten 2025 * | 119 mln. 128 mln. | EV/omzet 2025 * | 1,62 x |
K/w-verhouding 2024 * |
-300
x | K/w-verhouding 2025 * |
40,9
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,66% |
Recentste transcriptie over PHARMING GROUP
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Sijmen de Vries
CEO | Chief Executive Officer | 65 | 13-10-08 |
Jeroen Wakkerman
DFI | Director of Finance/CFO | 55 | 16-11-20 |
Anurag Relan
CTO | Chief Tech/Sci/R&D Officer | 52 | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Mark Pykett
BRD | Director/Board Member | 60 | 11-12-20 |
Leonard Kruimer
BRD | Director/Board Member | 66 | 19-05-21 |
Sijmen de Vries
CEO | Chief Executive Officer | 65 | 13-10-08 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,83% | 661 mld. | |
+27,00% | 566 mld. | |
-6,76% | 352 mld. | |
+20,34% | 332 mld. | |
+3,00% | 283 mld. | |
+13,09% | 231 mld. | |
+5,46% | 200 mld. | |
-9,61% | 195 mld. | |
-6,26% | 145 mld. |
- Beurs
- Aandelen
- Koers PHARM
- Koers